Potential Role and Therapeutic Interests of Myo-Inositol in Metabolic Diseases

The 2013 document reviews the therapeutic potential of myo-inositol (MI) supplementation in metabolic diseases, particularly for insulin resistance-related disorders such as polycystic ovary syndrome (PCOS), gestational diabetes mellitus, metabolic syndrome, and diabetic complications like neuropathy and nephropathy. It discusses the metabolism of MI, its insulin-mimetic properties, and the impact of MI depletion on diabetic complications. The document cites several randomized controlled trials (RCTs) that demonstrate the benefits of MI supplementation in improving insulin sensitivity and metabolic parameters, particularly in women with PCOS and gestational diabetes. One study with 92 participants showed positive effects on hyperinsulinemia and hormonal parameters in overweight patients with PCOS. However, the document emphasizes the need for larger and more diverse clinical trials to confirm these findings and to explore the potential of MI supplementation for a broader population at risk of insulin resistance.